A stock photo of a China's flag (Canva) (Reuters) – China’s National Medical Products Administration has approved domestic drugmaker Innovent Biologics’ weight control peptide injection’s entry into the market, the regulator said in a statement on Friday. ADVERTISEMENT Share this ArticlePrevious ArticleComelec lifts suspension on Eric Yap’s proclamation as Benguet repNext ArticlePH-US deal to fund technical aid for freight cargo railway projectBeijing Newsroom, Reuters Other News GenCorp counsel admits ₱2.14-M payouts to Duterte November 12, 2026 Gov’t to open EDSA bus lanes to ASEAN convoys November 11, 2026 MMDA releases traffic plan ahead of ASEAN Summit November 11, 2026 Marcos trust, performance scores decline – OCTA survey November 11, 2026 Duterte defense witnesses face questions over property, salary re ... November 11, 2026 Sandiganbayan suspends Romualdez for 90 days November 11, 2026